This biologic Ustekinumab was recently approved by the FDA for Crohn's - the stats on responders/remission are interesting to compare to Rem-L
So here they chose 628 patients who had failed to respond to conventional treatment, of those 397 responded to Ustekinumab and of those say 400 who responded approx 50% of them were in remission at 44 weeks - so your total numbers for remission are 200/628 or well less than 30%.
https://www.nejm.org/doi/full/10.1056/nejmoa1602773
oh and if you're interested have a look at the side effects profiles of the current treatments - most of these are immunosuppressants meaning you're at risk of TB or sepsis at best at worst increasing risk of serious cancers
https://www.webmd.com/ibd-crohns-disease/crohns-disease/crohns-biologics
- Forums
- ASX - By Stock
- MSB
- Crohn’s Disease
Crohn’s Disease, page-50
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.02 |
Change
0.005(0.50%) |
Mkt cap ! $1.158B |
Open | High | Low | Value | Volume |
$1.02 | $1.02 | $1.00 | $1.192M | 1.182M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 154631 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 36481 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 156491 | 1.010 |
16 | 102452 | 1.005 |
15 | 142729 | 1.000 |
9 | 211867 | 0.995 |
10 | 573404 | 0.990 |
Price($) | Vol. | No. |
---|---|---|
1.015 | 37629 | 13 |
1.020 | 223939 | 20 |
1.025 | 107897 | 9 |
1.030 | 76500 | 7 |
1.035 | 78950 | 4 |
Last trade - 13.45pm 19/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |